Please assess the completion status of the following clinical trial:

Trial Title: Influence of Dexmedetomidine or Propofol on ICU Delirium

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients (age 18 years or older) in a state of delirium (hyperactive ore mixed type) upon detection in the ICU (i.e., ICDSC \>3).~Exclusion Criteria:~* Hypersensitivity to the active substance~* Advanced heart block (grade 2 or 3) unless implanted pacemaker~* Uncontrolled hypotension~* Severe cardiac dysfunction~* Bradycardia~* Egg allergy~* Soybean/soy allergy~* Age below 18 years~* Terminal state~* Pregnancy~* Active psychosis (of non organic origin = functional disturbances)~* Status epilepticus or postictal states following seizures on EEG

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dexmedetomidine (Type: EXPERIMENTAL): Dexmedetomidine is a potent selective α-2-adrenergic receptor agonist frequently used for sedation in the ICU, also among critically ill patients. It promotes sedation, anxiolysis, and moderate analgesia with minimal respiratory depression and has been shown to reduce severity and duration of ICU delirium.
- Propofol (Type: ACTIVE_COMPARATOR): Standard therapy for ICU delirium.

Based on this trial design, predict the completion outcome and termination type (if applicable).